TY - JOUR
T1 - Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers
AU - Aparicio, Ana M.
AU - Shen, Li
AU - Tapia, Elsa Li Ning
AU - Lu, Jing Fang
AU - Chen, Hsiang Chun
AU - Zhang, Jiexin
AU - Wu, Guanglin
AU - Wang, Xuemei
AU - Troncoso, Patricia
AU - Corn, Paul
AU - Thompson, Timothy C.
AU - Broom, Bradley
AU - Baggerly, Keith
AU - Maity, Sankar N.
AU - Logothetis, Christopher J.
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2016/3/15
Y1 - 2016/3/15
N2 - Purpose: Morphologically heterogeneous prostate cancers that behave clinically like small-cell prostate cancers (SCPC) share their chemotherapy responsiveness. We asked whether these clinically defined, morphologically diverse, "aggressive variant prostate cancer (AVPC)" also share molecular features with SCPC. Experimental Design: Fifty-nine prostate cancer samples from 40 clinical trial participants meeting AVPC criteria, and 8 patienttumor derived xenografts (PDX) from 6 of them, were stained for markers aberrantly expressed in SCPC. DNA from 36 and 8 PDX was analyzed by Oncoscan for copy number gains (CNG) and losses (CNL). We used the AVPC PDX to expand observations and referenced publicly available datasets to arrive at a candidate molecular signature for the AVPC. Results: Irrespective of morphology, Ki67 and Tp53 stained ≥10% cells in 80% and 41% of samples, respectively. RB1 stained <10% cells in 61% of samples and AR in 36%. MYC (surrogate for 8q) CNG and RB1 CNL showed in 54% of 44 samples each and PTEN CNL in 48%. All but 1 of 8 PDX bore Tp53 missense mutations. RB1 CNL was the strongest discriminator between unselected castration-resistant prostate cancer (CRPC) and the AVPC. Combined alterations in RB1, Tp53, and/or PTEN were more frequent in the AVPC than in unselected CRPC and in The Cancer Genome Atlas samples. Conclusions: Clinically defined AVPC share molecular features with SCPC and are characterized by combined alterations in RB1, Tp53, and/or PTEN. Clin Cancer Res; 22(6); 1520-30.
AB - Purpose: Morphologically heterogeneous prostate cancers that behave clinically like small-cell prostate cancers (SCPC) share their chemotherapy responsiveness. We asked whether these clinically defined, morphologically diverse, "aggressive variant prostate cancer (AVPC)" also share molecular features with SCPC. Experimental Design: Fifty-nine prostate cancer samples from 40 clinical trial participants meeting AVPC criteria, and 8 patienttumor derived xenografts (PDX) from 6 of them, were stained for markers aberrantly expressed in SCPC. DNA from 36 and 8 PDX was analyzed by Oncoscan for copy number gains (CNG) and losses (CNL). We used the AVPC PDX to expand observations and referenced publicly available datasets to arrive at a candidate molecular signature for the AVPC. Results: Irrespective of morphology, Ki67 and Tp53 stained ≥10% cells in 80% and 41% of samples, respectively. RB1 stained <10% cells in 61% of samples and AR in 36%. MYC (surrogate for 8q) CNG and RB1 CNL showed in 54% of 44 samples each and PTEN CNL in 48%. All but 1 of 8 PDX bore Tp53 missense mutations. RB1 CNL was the strongest discriminator between unselected castration-resistant prostate cancer (CRPC) and the AVPC. Combined alterations in RB1, Tp53, and/or PTEN were more frequent in the AVPC than in unselected CRPC and in The Cancer Genome Atlas samples. Conclusions: Clinically defined AVPC share molecular features with SCPC and are characterized by combined alterations in RB1, Tp53, and/or PTEN. Clin Cancer Res; 22(6); 1520-30.
UR - http://www.scopus.com/inward/record.url?scp=84962304309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962304309&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-1259
DO - 10.1158/1078-0432.CCR-15-1259
M3 - Article
C2 - 26546618
AN - SCOPUS:84962304309
SN - 1078-0432
VL - 22
SP - 1520
EP - 1530
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 6
ER -